Seaport Therapeutics, Inc.
SPTXNext catalyst
SPT-300
Major Depressive Disorder (MDD)
Get an email about SPTX's next catalysts
Track Seaport Therapeutics (SPTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
SPT-300 Phase 2 Est. Readout
Primary completion for SPT-300 trial (NCT07065240) in Major Depressive Disorder (MDD)
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPT-300 | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Frequently asked questions
What is in Seaport Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Seaport Therapeutics, Inc.'s (SPTX) pipeline across Phase 2. Its lead program is SPT-300 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Seaport Therapeutics, Inc.'s next FDA catalyst?→
Seaport Therapeutics, Inc.'s (SPTX) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SPTX biotech catalysts?→
Add SPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Seaport Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.